Lipum AB

LIPUM

SE0015660899

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 10:51:45 2024-05-03 am EDT			5-day change	1st Jan Change
6.6 ^SEK	-0.75%		+12.82%	+1.23%

Apr. 02	Lipum Strengthens Its Protection of the Drug Candidate Sol-116 Through A Patent Application for Inflammation-Driven Cancer	CI
Mar. 20	Flerie Invest AB cancelled the acquisition of remaining 67.99% stake in Lipum AB (OM:LIPUM).	CI

Lipum AB Reports Earnings Results for the Full Year Ended December 31, 2023

February 29, 2024 at 02:55 am EST

Lipum AB (publ) reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was SEK 0.165 million compared to SEK 0.496 million a year ago. Net loss was SEK 37.18 million compared to SEK 38.09 million a year ago.

Latest news about Lipum AB

Lipum Strengthens Its Protection of the Drug Candidate Sol-116 Through A Patent Application for Inflammation-Driven Cancer	Apr. 02	CI
Flerie Invest AB cancelled the acquisition of remaining 67.99% stake in Lipum AB (OM:LIPUM).	Mar. 19	CI
Lipum Recommends Shareholders to Not Accept Mandatory Cash Offer	Mar. 19	CI
Lipum AB Reports First Patient Included in the Ongoing Phase I Clinical Study with SOL-116	Mar. 19	CI
Flerie Invest AB made an offer to acquire remaining 67.99% stake in Lipum AB (OM:LIPUM) for SEK 41.8 million.	Mar. 05	CI
Lipum AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Lipum AB Advances SOL-116 into Phase 2	Feb. 29	CI
Lipum AB Reports Positive Interim Results from Clinical Phase 1 Study Showing that SOL-116 Reduces Plasma BSSL Levels in Healthy Subjects	Jan. 29	CI
Lipum AB Announces Nomination Committee Appointments	Dec. 18	CI
Biopharmaceutical Company Lipum Names New CEO	Nov. 15	MT
Lipum Names New CEO	Nov. 09	MT
Lipum AB Appoints Ola Sandborgh as Chief Executive Officer, Effective from December 1, 2023	Nov. 09	CI
Lipum AB Appoints Karin Franck-Larsson as CMO	Nov. 01	CI
Lipum AB Announces Final Stages of the Clinical Phase I Study with SOL-116	Nov. 01	CI
Lipum AB Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-31	CI
Lipum AB Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Lipum Signs Research Collaboration with Sweden's Karolinska Institute	23-08-08	MT
Lipum AB Enters Collaboration with the Karolinska Institute, Division of Rheumatology At the Department of Medicine in Sweden	23-08-08	CI
Lipum Elects Carl-Johan Spak as New Board Member	23-05-23	CI
Lipum AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Lipum AB Auditor Raises 'Going Concern' Doubt	23-04-18	CI
Lipum AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
Lipum's Ongoing Clinical Phase 1 Study Proceeds as Planned	23-03-23	CI
Lipum AB Announces the Nomination Committee for the 2023 Annual General Meeting	22-12-21	CI
Lipum AB Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-25	CI

Chart Lipum AB

Duration

Period

More charts

Company Profile

Lipum AB (publ) is a Sweden-based biopharmaceutical company specialized in discovery and development of new treatment for chronic inflammatory diseases. Lipum develops new biological medicine for treatment of chronic inflammatory diseases eg rheumatoid arthritis. Development is based on results from preclinical research, for example in well-established animal models for inflammatory arthritis. The prospective drug is an antibody directed against a new target molecule, the protein Bile Salt-Stimulated Lipase (BSSL). Lipum's antibody (SOL-116) has a different mechanism of action than the other drugs. Lipum's drug candidate SOL-116 is a humanized monoclonal antibody and is therefore categorized as a biological drug.

Sector

Pharmaceuticals

Calendar

2024-05-27 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
LIPUM AB	+1.23%	12.96M
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.51B
BIOGEN INC.	-15.94%	31.67B
UCB	+52.66%	24.62B
BIOMARIN PHARMACEUTICAL INC.	-14.50%	15.65B
INCYTE CORPORATION	-14.38%	12.07B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.97B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.81B
INNOVENT BIOLOGICS, INC.	-4.33%	8.5B

Biopharmaceuticals

Lipum AB

Equities

LIPUM

SE0015660899

Pharmaceuticals

Lipum AB Reports Earnings Results for the Full Year Ended December 31, 2023

Latest news about Lipum AB

Chart Lipum AB

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Biopharmaceuticals